Summary The aim of this investigation was to examine the possibility of analysing TP53 mutations in archival paraffin-embedded material with the constant denaturant gel electrophoresis (CDGE) method (Hollstein, 1991) . The TP53 gene, which is 20 kb long and consists of 11 exons and 10 introns, is located on the short arm of chromosome 17. It encodes a 393 amino acid phosphoprotein (55 kDa), normally expressed at a low level in cells.
One of the most studied genes in cancer research is the TP53 tumour-suppressor gene. Since its discovery in 1979 (Lane et al., 1979) it has been found to be the most commonly altered gene in human tumours (Hollstein, 1991) . The TP53 gene, which is 20 kb long and consists of 11 exons and 10 introns, is located on the short arm of chromosome 17. It encodes a 393 amino acid phosphoprotein (55 kDa), normally expressed at a low level in cells.
Several studies indicate that the role of this protein is to maintain the genomic integrity of the cell (Livingstone et al., 1992; Yin et al., 1992; Eyfj6rd et al., 1995) . How TP53 achieves this goal is still unclear but a picture is emerging. In response to DNA damage, TP53 induces cell-cycle arrest (Kastan et al., 1992) by downstream regulation of several genes such as the p2] gene (El-Deiry et al., 1993 , which induces G1 cell-cycle arrest, and GADD45, which suppresses cell growth, inhibits DNA replication and induces DNA repair (Smith et al., 1994; Zhan et al., 1994) . The G1 arrest provides time for DNA repair before the cell replicates its DNA in the S-phase. Studies also indicate that TP53 might have a role in apoptosis (Lowe et al., 1993) and now more recently in DNA repair (Wang et al., 1994 . All these findings emphasise the importance of TP53's role as the guardian of the genome' (Lane, 1992) .
As reviewed by Greenblatt et al. (1994) , inactivation of the TP53 protein (e.g. by mutations or interaction with cellular or viral proteins) has been implicated in the development of many types of human cancers and it may be a critical step in the formation of cancer because it affects the response of the cell to DNA damage.
Alterations of TP53 are common in breast cancer, although the reported mutation frequency does vary. Immunohistochemical studies (IHCs), based on detecting abnormal accumulation of TP53 protein, report that 16-58% of breast tumours show immunostaining indicating mutation (Lipponen et al., 1993; Cunningham et al., 1994; MacGrogan et al., 1995) whereas DNA-based methods find TP53 mutations in 14-40% of the tumours analysed (Elledge et al., 1993; Saitoh et al., 1994; Bergh et al., 1995) . Several studies show that TP53 abnormalities (TP53 overexpression and/or TP53 mutations) are an indicator of increased malignant potential and worse prognosis in breast cancer patients (Andersen et al., 1993; Barnes et al., 1993; Bergh et al., 1995; Borg et al., 1995; MacGrogan et al., 1995; Thorlacius et al., 1995 DNA preparation DNA was extracted from tumour tissues embedded in paraffin blocks as previously described (Wright et al., 1990 To confirm abnormalities detected with the CDGE method the samples were reamplified and submitted to DGGE electrophoresis (perpendicular denaturant gradient gel electrophoresis). Samples that showed aberrantly migrating bands with both methods were considered to be mutants. PCR fragments with mobility shifts in exon 6 were digested with the restriction enzyme TaqI to detect the presence of the neutral A>G polymorphism in codon 213. Mutations were further confirmed by direct sequencing as described previously (B0rresen et al., 1991) . (89) 5 (3) 16 (8) 75 (41) 106 (59) 79 (52) 73 (48) 39 (35) 72 (65) 51 (50) 50 (50) 39 (27) 58 (40) Figure 3 ).
TP53 mutation analyses in archival breast carcinomas S Gretarsdottir et al 9 559 detecting mutations in the archival material. In four of the seven samples, where sequencing was unsuccessful, the mutation identification in CDGE and DGGE was based on the presence of heteroduplexes due to a very faint mutant band (Figures la and b) . The frequency of mutations in our TP53 analysis of the archival material is in concordance with previous findings. The observed TP53 mutation frequency, 16.1%, is similar to the frequency of 17.8% found in our previous study on fresh tumour tissue (Thorlacius et al., 1995) , slightly lower than the overall calculated frequency, 20% (B0rresen et al., 1995) but within the range of other reported frequencies, 14-40% (Elledge et al., 1993; Saitoh et al., 1994) . The mutation distribution (according to CDGE analysis) and the type of mutations (according to the DNA sequencing) identified is very similar to other studies (Greenblatt et al., 1994; B0rresen et al., 1995; Thorlacius et al., 1995) . The majority of mutations found are transitions (G: C> A: T). Transversion frequency is slightly lower in our data as no G: C > T: A and A: T> C: G transversions were identified.
Immunohistochemistry demonstrated TP53 nuclear accumulation in 31 % of the primary breast tumours. These results are also in agreement with our previous findings (33.7%, Thorlacius et al., 1995) using the CM-1 and DO-1 antibodies. A recent study using the DO-7 antibody (MacGrogan et al., 1995) reports a similar proportion of samples with nuclear staining (32%). Tissue sections used in the mutation and immunohistochemistry analysis were taken in succession from the same paraffin blocks, thus an identical tumour cell population was used in these two studies. We found a highly significant association between the presence of TP53 mutations (CDGE analysis) and TP53 (1994) , TP53 abnormalities are believed to be an early event in breast cancer tumour progression. In this study we found no differences in lymphnode involvement between patients with and without TP53 abnormalities. As metastatic lymph-node involvement is believed to be a time-dependent factor reflecting the chronological age of the breast tumour (Barr et al., 1992) our observation may be interpreted as support for the abovementioned conclusion of Greenblatt et al.
In the present investigation tumours with TP53 abnormalities tend to have aggressive biological behaviour reflected by less tumour differentiation and higher proliferation rate. It was therefore unexpected that, in the group as a whole, patients with tumour TP53 abnormalities had similar survival to patients with normal TP53 in their tumours. This finding differs from our previous results (Thorlacius et al., 1995) and results of many other investigations (Andersen et al., 1993; Barnes et al., 1993; Bergh et al., 1995; Borg et al., 1995 MacGrogan et al., 1995 shorter post-recurrence survival than patients with normal TP53 status. This seems to indicate that tumours with abnormal TP53 are more resistant to therapy than tumours with normal TP53. It is known that cancer chemotherapeutic drugs and radiation induce apoptosis (Kerr et al., 1994) . Studies on transformed cells, show that the TP53 gene is an important component of the apoptotic pathway (Clarke et al., 1993; Lowe et al., 1993) . In vivo experiments in mice show that tumour response to gamma irradiation and to the chemotherapeutic drug doxorubicin is under the influence of the TP53 status (Lowe et al., 1994) . These results show that defects in apoptosis caused by TP53 inactivation can produce treatment-resistant tumours. A recent study (Bergh et al., 1995) shows that adjuvant therapy, especially with tamoxifen, along with radiotherapy seems to be of less value for breast cancer patients with TP53 mutations and node-positive tumours than patients without mutations.
In conclusion our data show that it is possible to use archival material for TP53 mutation analysis and that results are comparable with those obtained from fresh tumour tissue. There was a slight trend towards poorer prognosis in overall and breast cancer corrected survival for patients with TP53 abnormalities. A significant effect, however, was seen in postrecurrence survival, suggesting that poor response to therapy may be related to altered TP53 function.
